SG11201909735YA - Therapeutic compounds and compositions, and methods of use thereof - Google Patents

Therapeutic compounds and compositions, and methods of use thereof

Info

Publication number
SG11201909735YA
SG11201909735YA SG11201909735YA SG11201909735YA SG 11201909735Y A SG11201909735Y A SG 11201909735YA SG 11201909735Y A SG11201909735Y A SG 11201909735YA SG 11201909735Y A SG11201909735Y A SG 11201909735YA
Authority
SG
Singapore
Prior art keywords
international
pct
methods
designated states
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Zak
F Anthony Romero
Yun-Xing Cheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201909735YA publication Critical patent/SG11201909735YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201909735Y 2017-05-22 2018-05-21 Therapeutic compounds and compositions, and methods of use thereof SG11201909735YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017085276 2017-05-22
US201862640865P 2018-03-09 2018-03-09
PCT/EP2018/063262 WO2018215389A1 (en) 2017-05-22 2018-05-21 Therapeutic compounds and compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201909735YA true SG11201909735YA (en) 2019-11-28

Family

ID=62386421

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909735Y SG11201909735YA (en) 2017-05-22 2018-05-21 Therapeutic compounds and compositions, and methods of use thereof

Country Status (19)

Country Link
US (3) US10307426B2 (ru)
EP (1) EP3630766A1 (ru)
JP (2) JP7256757B2 (ru)
KR (1) KR20200010390A (ru)
CN (1) CN110650959B (ru)
AU (1) AU2018274577A1 (ru)
BR (1) BR112019024322A2 (ru)
CA (1) CA3061236A1 (ru)
CL (1) CL2019003258A1 (ru)
CO (1) CO2019010559A2 (ru)
CR (1) CR20190520A (ru)
MA (1) MA48942A (ru)
MX (1) MX2019013308A (ru)
PE (1) PE20200341A1 (ru)
PH (1) PH12019502601A1 (ru)
RU (1) RU2769696C2 (ru)
SG (1) SG11201909735YA (ru)
TW (1) TW201902896A (ru)
WO (1) WO2018215389A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018274577A1 (en) * 2017-05-22 2019-10-10 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020257143A1 (en) * 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
CA3140024A1 (en) 2019-06-18 2020-12-24 Mark Edward Zak Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
JP7039045B2 (ja) * 2019-08-26 2022-03-22 株式会社フェニックスバイオ ヒト脂肪肝モデル細胞
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8401486A1 (es) 1981-11-10 1983-12-01 Wellcome Found Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
US4847256A (en) 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5705625A (en) 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
US7070972B1 (en) 1995-01-13 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Janus family kinases and identification of immune modulators
EP0842195A1 (en) 1995-07-06 1998-05-20 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US7091020B1 (en) 1995-12-05 2006-08-15 Incyte Corporation Human Jak2 kinase
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
FR2791562B1 (fr) 1999-03-29 2004-03-05 Oreal Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
AU778450B2 (en) 1999-07-02 2004-12-09 Eisai R&D Management Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
SK287188B6 (sk) 1999-12-10 2010-02-08 Pfizer Products Inc. Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
EP1458682B1 (en) 2001-12-20 2006-08-30 Bayer HealthCare AG 1,4-dihydro-1,4-diphenylpyridine derivatives
MXPA04010441A (es) 2002-04-23 2005-02-14 Shionogi & Co Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo.
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
EP1643960A2 (en) 2003-07-02 2006-04-12 Merck & Co., Inc. Arylsulfonamide derivatives
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US20060030536A1 (en) 2004-04-09 2006-02-09 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2007535560A (ja) 2004-04-28 2007-12-06 シーブイ・セラピューティクス・インコーポレイテッド A1アデノシンレセプターアンタゴニスト
WO2006004702A1 (en) 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
EP1812440B1 (en) 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Lck阻害剤としての縮合複素環
WO2007039797A1 (en) 2005-10-03 2007-04-12 Pfizer Products Inc. Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
AR057979A1 (es) 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
US7776865B2 (en) * 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2007048065A2 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones as casein kinase ii (ck2) modulators
WO2007065664A2 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
US8541406B2 (en) 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
EP2102211A2 (en) 2006-11-20 2009-09-23 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
JP5681855B2 (ja) 2007-10-12 2015-03-11 アストラゼネカ エービー プロテインキナーゼの阻害剤
JP5779778B2 (ja) 2007-11-28 2015-09-16 ダナ−ファーバー キャンサー インスティテュート インク.Dana−Farber Cancer Institute, Inc. Bcr−ablの低分子のミリスチン酸エステル阻害剤及びその使用方法
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2288260A4 (en) 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
US8252791B2 (en) 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
MX2011008335A (es) 2009-02-06 2011-09-06 Ortho Mcneil Janssen Pharm Novedosos compuestos heterociclicos biciclicos sustituidos como moduladores de la gamma secretasa.
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EA022120B1 (ru) 2009-10-20 2015-11-30 Целльзом Лимитид Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak
BR112012023382A2 (pt) 2010-03-17 2018-05-15 F Hoffmann La Roche Ag T compostos, composições e métodos de uso de imidazopiridina.
EA201291038A1 (ru) 2010-04-30 2013-05-30 Целльзом Лимитид Соединения пиразола в качестве ингибиторов jak
CN110003219A (zh) 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2688872A4 (en) 2011-03-22 2014-08-27 Merck Sharp & Dohme AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2892899B1 (en) 2012-09-06 2018-03-21 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
CN104854090B (zh) 2012-11-09 2017-12-15 雅各布斯制药公司 杂芳基衍生物和其用途
EP3019171B1 (en) 2013-07-11 2018-09-05 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
EP3066094B1 (en) 2013-11-08 2020-01-08 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
UA121658C2 (uk) * 2014-05-23 2020-07-10 Ф. Хоффманн-Ля Рош Аг Сполуки 5-хлордифторметоксифенілпіразолопіримідину як інгібітори янус-кінази
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EP3145522B1 (en) 2014-05-23 2020-12-23 Phibro Animal Health Corporation Combination, composition, and method of administering the combination or composition to animals
JP6734860B2 (ja) 2014-11-06 2020-08-05 リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. 置換ピラゾロ[1,5−a]ピリミジンおよび医療疾患の治療におけるその使用
WO2016144844A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Carboxamide inhibitors of irak4 activity
EP3268004B1 (en) 2015-03-12 2019-12-18 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
EP3267996B1 (en) 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
EP3268006B1 (en) 2015-03-12 2020-01-08 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of irak4 activity
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
WO2017140825A1 (en) 2016-02-18 2017-08-24 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof
AU2017385543A1 (en) 2016-12-29 2019-05-23 F. Hoffmann-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof
CN110494434B (zh) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
AU2018274577A1 (en) * 2017-05-22 2019-10-10 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
CN110678467B (zh) 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法

Also Published As

Publication number Publication date
US10307426B2 (en) 2019-06-04
CN110650959B (zh) 2023-04-18
KR20200010390A (ko) 2020-01-30
AU2018274577A1 (en) 2019-10-10
CO2019010559A2 (es) 2019-10-09
RU2019141734A (ru) 2021-06-23
CL2019003258A1 (es) 2020-04-17
MX2019013308A (es) 2020-02-12
WO2018215389A1 (en) 2018-11-29
MA48942A (fr) 2020-04-08
EP3630766A1 (en) 2020-04-08
US20190240227A1 (en) 2019-08-08
PE20200341A1 (es) 2020-02-14
US20180333416A1 (en) 2018-11-22
CN110650959A (zh) 2020-01-03
TW201902896A (zh) 2019-01-16
BR112019024322A2 (pt) 2020-06-16
JP2023058657A (ja) 2023-04-25
JP2020520959A (ja) 2020-07-16
CR20190520A (es) 2020-01-21
JP7256757B2 (ja) 2023-04-12
CA3061236A1 (en) 2018-11-29
RU2769696C2 (ru) 2022-04-05
US20200352951A1 (en) 2020-11-12
RU2019141734A3 (ru) 2021-08-10
PH12019502601A1 (en) 2020-06-08

Similar Documents

Publication Publication Date Title
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201908670SA (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201808878UA (en) Heterocyclic compounds as ret kinase inhibitors
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201407200TA (en) Liquid formulation
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201407988UA (en) Process for improved opioid synthesis
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders